SciClone Pharma soars, Zadaxin channel inventory build-up resolved

SciClone Pharmaceuticals (SCLN) rises 14% premarket on the heels of its Q2 report.

CEO Friedhelm Blobel notes that although H1 revenue performance was "disappointing," the Zadaxin channel inventory build-up responsible for sluggish sales growth has been "resolved."

FY13 guidance: Zadaxin sales should "rebound" in H2, growing 50% versus H1. FY13 revenues are seen at $135-145M. Full year adjusted EPS should come in between $0.55-0.61.

The company also says it will file its previously delayed Q1 10-Q "on or around" August 9 after consulting with the SEC. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs